Document Detail


Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia.
MedLine Citation:
PMID:  9368477     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The detection of dysplastic features of hematopoiesis in de novo acute myeloid leukemia (AML) by light microscopy is defined as AML with trilineage myelodysplasia (AML/TLMD). The prognostic relevance of these dysplastic features for patients with de novo AML remains unclear. In order to evaluate the role of dysplasia in de novo AML, bone marrow aspirates from 69 patients were analyzed prospectively and investigated separately for erythropoiesis, granulopoiesis and megakaryopoiesis by three independent investigators. The overall complete remission (CR) rate was 48.8% and partial remission (PR) or nonresponders constituted 52.2% of the patients investigated. The median overall survival time was 5 months with a disease-free interval of 3.5 months for all patients. Dysgranulopoiesis (DysG) was observed in 30.4%, dysmegakaryopoiesis (DysM) in 50.7%, and dyserythropoiesis (DysE) in 43.5%. Of all patients, 26.0% showed trilineage dysplastic features and were thus classified as AML/TLMD. A significantly worse prognosis (Kaplan-Meyer plot, Student's t-test) was calculated for those patients with detection of only DysG (p = 0.002), DysM (p = 0.02), DysE (p = 0.04) as compared with patients without any dysplastic signs. An unfavorable karyotype was correlated with patients showing DysG (P = 0.02) and DysM (P = 0.04). For these patients with an unfavorable karyotype, the occurrence of any dysplastic features had no additional prognostic impact. Dysplastic features (DysG, DysM, DysE) seem to be an important prognostic factor in de novo AML correlating with short overall survival. DysG and DysM correlated well with the appearance of unfavorable chromosomal abnormalities. It may be reasonable to assume that patients with dysplastic features should be considered for more aggressive treatment schedules at the time of diagnosis.
Authors:
C Kahl; A Florschütz; G Müller; K Jentsch-Ullrich; M Arland; S Leuner; A Franke; H G Höffkes
Related Documents :
3886417 - Cyclosporin a in marrow transplantation for leukemia and aplastic anemia.
279357 - Delayed hypersensitivity skin reactions in the induction phase of remission in acute no...
7537117 - Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patien...
1528067 - Morphologic, immunologic and cytogenetic studies in acute myeloid leukemia following oc...
9085167 - Thyroid neoplasia and familial adenomatous polyposis/gardner's syndrome.
19676147 - Plasma osteoprotegerin is an independent risk factor for mortality and an early biomark...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of hematology     Volume:  75     ISSN:  0939-5555     ISO Abbreviation:  Ann. Hematol.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-12-04     Completed Date:  1997-12-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  91-4     Citation Subset:  IM    
Affiliation:
Department of Medicine, Otto-von-Guericke University of Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Female
Hematopoiesis / physiology*
Humans
Karyotyping
Leukemia, Myeloid, Acute / complications,  genetics,  physiopathology*
Male
Middle Aged
Myelodysplastic Syndromes / complications,  pathology*,  physiopathology
Prognosis
Prospective Studies
Survival Analysis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Absence of mutations in the RET gene in acute myeloid leukemia.
Next Document:  C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantati...